We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
- Authors
Hicks, Charles B; Cahn, Pedro; Cooper, David A; Walmsley, Sharon L; Katlama, Christine; Clotet, Bonaventura; Lazzarin, Adriano; Johnson, Margaret A; Neubacher, Dietmar; Mayers, Douglas; Valdez, Hernan; RESIST investigator group
- Abstract
Treatment options for HIV-1 infected individuals who have received extensive previous antiretroviral therapy are limited. We compared efficacy and safety of the novel non-peptidic protease inhibitor tipranavir co-administered with ritonavir plus an optimised background regimen with that of an investigator-selected ritonavir-boosted comparator protease inhibitor (CPI-ritonavir) in such patients.
- Publication
Lancet (London, England), 2006, Vol 368, Issue 9534, p466
- ISSN
1474-547X
- Publication type
Journal Article
- DOI
10.1016/S0140-6736(06)69154-X